Erythropoietin in Hemolytic Uremic Syndrome

• Status: Completed
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital General de Niños Pedro de Elizalde
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Post diarrheal HUS: Prodrome of enteritis followed by microangiopathic hemolytic anemia, thrombocytopenia and signs of renal damage (increased plasma creatinine, proteinuria, and / or hematuria). Proven STEC infection wiil not be required to enter into the study.

Exclusion Criteria:

• Atypical HUS

• HUS associated with systemic diseases (pneumococcal infection, HIV, Systemic lupus erythematosus) or drugs

• Anemia or known kidney disease

• Previously transfused or treated with erythropoietin

• Contraindications to erythropoietin